SPOTLIGHT -
April 26th 2024
What is new in research on posttraumatic stress disorder?
April 12th 2024
A supplemental new drug application was submitted for the combination of brexpiprazole and sertraline in the treatment of PTSD in adults.
April 4th 2024
Lykos Therapeutics recently received priority review of MDMA-assisted therapy for patients with PTSD. Check out the latest research update here!
March 29th 2024
What is new in research on bipolar disorder?
March 13th 2024
These 5 processes provide a focus for patients with PTSD...
The Week in Review: March 4-8
From an update on Prism for PTSD to the efficacy of home-use transcranial direct current stimulation for MDD, here are highlights from the week in Psychiatric Times.
Read More
Study Highlights Efficacy of Prism for PTSD in Alleviating Chronic PTSD Symptoms
The therapy is the first self-neuromodulation device for PTSD approved by the US Food and Drug Administration.
Psychiatry in the News: February 2024
Here are some updates from the world of psychiatry throughout the month of February.
The Week in Review: February 12-16
From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.
FDA Accepts, Grants Priority Review of NDA for MDMA-Assisted Therapy for PTSD
The treatment's PDUFA date is set for August 11, 2024.
Medication Pipeline: Antidepressants and ADHD Rx
Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.
Psychiatry in the News: January 2024
Here are some updates from the world of psychiatry throughout the month of January.
From the Pages of Psychiatric Times: January 2024
The experts weighed in on a wide variety of psychiatric issues for the January 2024 issue of Psychiatric Times.
The Week in Review: January 8-12
From substance use disorders in physicians to new research on the efficacy of MDMA-assisted therapy for PTSD, here are highlights from the week in Psychiatric Times.
Medication-Assisted Psychotherapy: The Past and Future of Psychiatry
Medication Pipeline: Schizophrenia and PTSD
Here's an update on which medications are on the horizon for the treatment of schizophrenia and PTSD.
Resolution #4: Improving the Treatment of Trauma in Israel, Gaza, and Elsewhere
What can we learn from war trauma?
Landmark Study Highlights Efficacy of MDMA-Assisted Therapy for PTSD
In a first of its kind study, MDMA-assisted therapy successfully supported patients with PTSD.
Processes and Interventions That Drive Improvement in PTSD
Here are 5 processes to provide focus and empowerment for patients with PTSD.
The Week in Review: January 1-5
From a groundbreaking new launch for PTSD in the United States to connections between antidepressant treatment and metabolic syndrome, here are highlights from the week in Psychiatric Times.
PTSD Research Roundup: January 5, 2024
First FDA-Approved Self-Neuromodulation Device for PTSD Officially Launches in the US
The device is now available at 2 US clinics, with training and installation currently underway at several other locations.
Psychiatry in the News: December 2023
Here are some updates from the world of psychiatry throughout the month of December.
Preliminary Phase 2 Data Shows Psilocybin for PTSD Is Well-Tolerated
Initial data from phase 2 safety profile for psilocybin in the treatment of PTSD indicates the treatment is well-tolerated.
NDA Submitted for MDMA-Assisted Therapy for Posttraumatic Stress Disorder
MAPS has submitted an NDA for MDMA-assisted therapy for patients with posttraumatic stress disorder.
Psychedelics Research Roundup: November 17, 2023
What is new in research on psychedelics?
From the Pages of Psychiatric Times: October 2023
The experts weighed in on a wide variety of psychiatric issues for the October 2023 issue of Psychiatric Times.
The Week in Review: October 16-20
From long-acting injectable antipsychotics for managing schizophrenia to mental health responses to the recent conflict in Israel, here are highlights from the week in Psychiatric Times.
Concurrent Treatment of Eating Disorders and PTSD Leads to Long-Term Recovery
Concurrent treatments targeting eating disorders and PTSD are needed to help these patients with complex conditions.
You Have to Say Hello Before You Can Say Goodbye
Residues of past traumatic events can deeply impact our present experiences and our functioning in ways that we are not aware of consciously. We must process and let go of these experiences in order to heal.
Running Wild: The Impact of Wildfires on Mental Health
Climate change plays a pivotal role in the recent surge of wildfires, and their impact on mental health. How can you, as a clinician, help those impacted by these disasters, specifically children and adolescents?
A New Approach to Reducing Suicide Risk Among Veterans
New data from the Suicide and Trauma Reduction Initiative for Veterans at Ohio State University indicates the most effective interventions to prevent suicide risk among veterans.
Mental Health in the Mideast Crisis
Psychiatry will be needed to help heal the mental wounds in the Mideast.
Psychiatry in the News: September 2023
Here are some updates from the world of psychiatry throughout the month of September.
Topline Phase 2 Data Support Efficacy, Tolerability, and Favorable Safety of Treatment for PTSD
The ongoing clinical trial is also studying the drug’s efficacy in the treatment of MDD.